Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
Interventions: PM01183 + paclitaxel +/- bevacizumab; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer, High Grade Ovarian Serous
Interventions: PET/MRI, Contrast enhanced CT; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms
Interventions: CNTO 328; Anti-interleukin-6 monoclonal antibody; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Houston, Texas

Conditions: Thyroid Cancer
Interventions: PET Imaging, 18F-tetrafluoroborate (18F-TFB); Procedure · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Pancreatitis, Diabetes
Interventions: autologous mesenchymal stromal cell; Biological
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 69 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Celiac Disease, Hypothyroidism, Celiac Sprue, Malabsorption
Interventions: Not listed
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Type 2 Diabetes Mellitus (T2DM), Time Restricted Eating, Microalbuminuria
Interventions: Time Restricted Eating; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pancreatic Neuroendocrine Tumor
Interventions: RAD001, Temozolomide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Pancreatic Cancer
Interventions: Interviews; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Function, Preservation of Ovarian Function
Interventions: GnRH antagonist; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 10 Years to 21 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions: BT8009, Pembrolizumab; Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more

Conditions: Carcinoma, Pancreatic Ductal
Interventions: Paclitaxel and gemcitabine; Drug
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Type 1 Diabetes
Interventions: Reinforcement for wearing CGM; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 26 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pancreatic Cancer
Interventions: gemcitabine hydrochloride, oxaliplatin; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 18
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more

Conditions: Diabetes Mellitus
Interventions: Onyx BG Meter / App System; Device
Lead sponsor: Ascensia Diabetes Care; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Escondido, California

Conditions: Diabetes Mellitus, Type 2, HIV Infections, PreDiabetes
Interventions: MTM + ILI, Standard MTM; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetes Mellitus (Type 2)
Interventions: Speak Up! Video; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Hines, Illinois • Crown Point, Indiana

Conditions: Type 1 Diabetes
Interventions: AID + InsuLearn-SMA, AID + CC; Device
Lead sponsor: Melissa J. Schoelwer; Other
Eligibility: 14 Years to 21 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions: Cabozantinib + Atezolizumab; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Pancreatic Cancer
Interventions: Nivolumab + Cabiralizumab, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York • Seattle, Washington

Conditions: Metabolic Syndrome X
Interventions: Low-carbohydrate and high-carbohydrate diets; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 64 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: T1DM - Type 1 Diabetes Mellitus
Interventions: 13 CGM (continuous glucose monitor); Device
Lead sponsor: Sinocare; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Malignant Ascites
Interventions: catumaxomab; Drug
Lead sponsor: Neovii Biotech; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 18
States / cities: Tucson, Arizona • La Jolla, California • Stanford, California + 14 more

Conditions: Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine); Drug
Lead sponsor: GRADE Study Group; Other
Eligibility: 30 Years and older
Enrollment: 7,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more

Search by objective public record fields.

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer

Mesenchymal Stem Cell and Islet Co-transplantation

Detection of Celiac Disease in Patients With Hypothyroidism

Time Restricted Eating in Patients With Microalbuminuria

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Barriers And Facilitators To Clinical Trial Enrollment: A Qualitative Study Of Pancreatic Cancer Patients

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer

A Reinforcement Approach to Increase Use of CGM

Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer

Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System

Food as Medicine for HIV and Diabetes

Empowering Veterans to Actively Communicate and Engage in Shared Decision Making in Medical Visits, A Randomized Controlled Trial

Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Comparison of Two Different Diets on Health Outcomes

The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes